AI Biotech XtalPi Closes $15M Series B Funding Round

XtalPi Inc., a Shenzen, China-based computation-driven pharmaceutical technology company, closed a $15m Series B funding round.

The round was led by Sequoia China, with participation from Google and existing investor Tencent. Existing investors also include ZhenFund and FreeS Fund.

The company, which has raised over $20m to date, will use the funds to develop new computational models built on big data generated from its computing platform, to expand the business into adjacent areas along the pharmaceutical value chain, and build a prediction-driven research lab that integrates its R&D platform with wet-bench laboratory technologies.

Led by Co-founder and Chairman of the Board Dr. Shuhao Frank Wen, XtalPi offers Intelligent Digital Drug Discovery and Development (ID4) platform combining artificial intelligence, quantum physics, and high-performance cloud computing to predict many important characteristics of small-molecule drugs and solid forms enabling pharmaceutical companies and research organizations to increase their accuracy and success rate at critical stages of drug R&D.



Join the discussion